Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Up 4.4% – Still a Buy?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report)’s stock price traded up 4.4% during mid-day trading on Monday. The company traded as high as $23.75 and last traded at $22.54. Approximately 35,776 shares changed hands during trading, a decline of 92% from the average session volume of 433,881 shares. The stock had previously closed at $21.60.

Analysts Set New Price Targets

Several research firms have recently commented on DMRA. Guggenheim initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, November 6th. They set a “buy” rating and a $59.00 price target on the stock. Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Finally, TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock has an average rating of “Buy” and a consensus target price of $46.38.

Check Out Our Latest Analysis on Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Trading Up 4.1%

The firm has a fifty day simple moving average of $22.19 and a 200 day simple moving average of $25.61. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -15.95 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.12. On average, equities analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Jennifer Jarrett bought 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction that occurred on Friday, September 25th. The stock was purchased at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the transaction, the chief executive officer directly owned 512,500 shares in the company, valued at $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently made changes to their positions in the business. Braidwell LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $42,146,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter worth about $7,398,000. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter worth about $303,000. Finally, Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $260,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

(Get Free Report)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Further Reading

Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.